Loading clinical trials...

Risk Factors and Deep Learning Model for CI-AKI | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Risk Factors and Deep Learning Model for CI-AKI

Investigation and Early Risk Prediction of Acute Kidney Injury Caused by Iodinated Contrast Agents: Development of CI-AKIDPi Model Based on Interpretable Deep Learning

NCT06596785•Xiao Li，MD

View on ClinicalTrials.gov

Summary

Contrast-associated acute kidney injury (CI-AKI) is a sudden and significant decline in renal function resulting from the use of a contrast agent.

Detailed Description

Contrast-associated acute kidney injury (CI-AKI) is a sudden and significant decline in renal function resulting from the use of a contrast agent. Despite the frequent use of iodinated contrast agents in medical investigations, predictive models for CI-AKI are scarce. This study aimed to construct and validate interpretable deep learning models for the early risk prediction of acute kidney injury (AKI) associated with iodinated contrast agents.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•patients who received iodinated contrast agents during hospitalization
•age ≥ 18 years
•hospitalization length ≥ 48 hours
•at least two serum creatinine tests during hospitalization

Exclusion Criteria

•patients with stage 4 or 5 chronic kidney disease prior to admission
•patients undergoing hemodialysis, hemofiltration or peritoneal before admission
•a history of nephrectomy or kidney transplantation during hospitalization
•incomplete clinical information
•Serum creatinine always ≤ 40 μmol/L during hospitalization

Locations (1)

The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Jinan, Shandong, China

Key Dates

Start Date

June 1, 2024

Primary Completion Date

March 1, 2025

Completion Date

June 1, 2025

Last Updated

September 19, 2024

Enrollment

2,000

ACTUAL participants

Conditions

AKI - Acute Kidney Injury

Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2

NCT07106151

AKIAKI - Acute Kidney Injury+1 more

View study

RECRUITING

Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy

NCT07294859

NephrectomyRenal Cell Cancer+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Risk Factors and Deep Learning Model for CI-AKI

Inclusion Criteria

Exclusion Criteria

Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2

Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy

Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane

Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI

Neurological Complications and ICU Workload After Emergency Repair of Acute Type A Aortic Dissection

Sevoflurane and Dexmedetomidine's Contrasting Renal Impacts After Non-Cardiac Surgery